Repligen Corporation

Theodore E Maione

Richard J Sharpe

Stefan Niewarowski

Jacquelynn J Cook

The subject invention pertains to compositions and methods of treatment of angiogenesis using PF4 and peptide fragments thereof.

Methods and compositions for treatment of angiogenic diseases

The subject invention pertain to methods of treating Kaposi's Sarcoma and ocular neovascularization using rPF4 and angiogenesis-inhibiting fragments of rPF4.

Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of a purified heparin binding fragment of PF4 or of recombinant PF4.

Heparin neutralization with platelet factor 4 fragments

The subject invention concerns a novel treatment for cancer. Specifically, the invention concerns the systemic administration of recombinant Platelet Factor Four (rPF4) to inhibit tumor growth in a mammal having metastatic cancer.

Systemic treatment of metastatic cancer with platelet factor 4

Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of purified PF4 or rPF4 or a heparin neutralizing fragment thereof.

Heparin neutralization with platelet factor 4

The subject invention pertains to the use of modified PF4 and recombinant PF4(rPF4) as well as modified analogs (mutants) of PF4, and peptide fragments thereof, to inhibit angiogenesis. The modified PF4, analogs, and certain fragments are shown to have utility for treating angiogenic diseases and for the inhibition of endothelial cell proliferation. Also, the subject invention concerns modification of PF4 which facilitate the targeting of the biological activity of PF4 to specific locations.

Modified PF4 compositions and methods of use

The subject invention pertains to the use of recombinant PF4 (rPF4) as well as full length novel analogs (mutants) of rPF4, and peptide fragments thereof, to inhibit angiogenesis. rPF4, analogs, and certain fragments are shown to have utility for treating angiogenic diseases and for the inhibition of endothelial cell proliferation.

Growing community of inventors

Wakefield, MA, United States of America

Theodore E Maione